Patient screening of Innovation Pharmaceuticals’ phase 1 trial in Jan
Category: #health  By Pankaj Singh  Date: 2019-12-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Patient screening of Innovation Pharmaceuticals’ phase 1 trial in Jan

Innovation pharmaceuticals is gearing for the roll out of patient screening for phase 1 trial in January that will apparently examine the significance of delayed release tablets for oral Brilacidin’s colonic delivery in healthy volunteers which will help in the treatment of Ulcerative Colitis.

A fortnight ago, Innovation Pharmaceuticals received green signal from Medicines and Healthcare products Regulatory Agency of the UK to kick off the Phase 1 trial. Apparently, the study is expected to assess oral Brilacidin’s delivery directly to the colon by using sophisticated delayed-release drug delivery technology pioneered by formulation partner of the company. Nevertheless, the study will also analyze toleration, safety and pharmacokinetics of oral Brilacidin.

Leo Ehrlich, CEO of Innovation Pharmaceuticals expects study to be completed in a short span of time and stated that dosing would lead to a slew of positive results for the company. He went on to add that he was sanguine of the efficacy and safety landscape of Brilacidin in IBD, given the clinical trial held in the past in Ulcerative Proctitis/Ulcerative Proctosigmoiditis.

Ehrlich was quoted expressing confidence pertaining to the commercial future and competitive landscape of oral rinse Brilacidin as a preventive OM drug candidate and the brand value it can bring to the company. The statement came in the wake of apparent aura surrounding the initial public offerings (IPOs) of Monopar Therapeutics and Galera Therapeutics.

He expressed his delight that their out-licensing partner is contemplating trials mid-year 2020. Ehrlich stressed the relevance of efficacious delivery of the drug directly into the colon, which would eventually help in wooing big pharmaceutical companies and would bolster differentiation.

The meeting of investors with pharmaceuticals companies having interest in Brilacidin is set to take place in January during the 2020 J.P Morgan Healthcare conference in San Francisco. Shareholders would be buoyed if a licensing deal for the Brilacidin-OM asset turns into a reality.
 

Source credit:

http://www.ipharminc.com/press-release/2019/12/26/innovation-pharmaceuticals-patient-screening-for-phase-1-trial-of-oral-brilacidin-in-ulcerative-colitis-program-on-track-for-early-january



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...